Abstract:Protein kinase inhibitors and epigenetic regulatory molecules are two main kinds of anticancer drugs developed in recent years. Both kinds of drugs harbor their own advantages and disadvantages in the treatment of cancer, and the development of small molecules which could target at kinases and epigenetic targets simultaneously can avoid the defects of drugs which only targets at kinases or epigenetic proteins. In this study, a series of 4,5-dihydro-[1,2,4]triazolo [4,3-f]pteridine derivatives were designed and synthesized based on the structure of PLK1 inhibitor BI-2536. Subsequent targets affinity screen and antiproliferative activity test led to the discovery of the most potent dual PLK1/BRD4 inhibitor 9b with good potency for both PLK1 (IC50 = 22 nM) and BRD4 (IC50 = 109 nM) as well as favorable antiproliferative activity against a panel of cancer cell lines. 9b could induce cell cycle arrest and apoptosis in acute myeloid leukemia cell line MV 4-11 in a concentration dependent manner. It could also downregulate the transcription of several proliferation-related oncogenes, including c-MYC, MYCN and BCL-2. Finally, in a MV4-11 mouse xenograft model, 9b exhibited favorable in vivo antitumor activity with 66% tumor growth inhibition (TGI) at a dose of 60 mg/kg while without obvious toxicity. This study thus provided us a start point for the development of new dual PLK1/BRD4 inhibitors as anticancer agents. (c) 2020 Elsevier Masson SAS. All rights reserved.

Design, Synthesis and Anti-Ovarian Cancer Activities of Thieno[2,3-D] Pyrimidine Based Chimeric BRD4 Inhibitor/nitric Oxide-Donator

Rational Design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol Derivatives As Novel Bromodomain-Containing Protein 4 Inhibitors.

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

Design, Synthesis and Biological Evaluation of Imidazolopyridone Derivatives As Novel BRD4 Inhibitors.

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Design, Synthesis and Biological Evaluation of Dihydroquinoxalinone Derivatives As BRD4 Inhibitors.

Design, Synthesis and Biological Evaluation of Novel 6-Phenyl-1,3a,4,10b-tetrahydro-2h-benzo[c]thiazolo[4,5-e]azepin-2-one Derivatives As Potential BRD4 Inhibitors.

Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors

Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.

Design, Synthesis and Biological Evaluation of 7-Methylimidazo[1,5-a]pyrazin-8(7h)-one Derivatives As BRD4 Inhibitors.

Design, Synthesis and Biological Evaluation of Novel O-2-(2,4-Dinitrophenyl) diazeniumdiolates as Anti-tumor Agents

Identification of 3,5-Dimethylisoxazole Derivatives As BRD4 Inhibitors for the Treatment of Colorectal Cancer.

Targeting Epigenetic Reader and Eraser: Rational Design, Synthesis and in Vitro Evaluation of Dimethylisoxazoles Derivatives As BRD4/HDAC Dual Inhibitors

Development of 7-Methylimidazo[1,5-a]pyrazin-8(7h)-one Derivatives As a Novel Chemical Series of BRD4 Inhibitors

Design, synthesis, and anticancer evaluation of ammosamide B with pyrroloquinoline derivatives as novel BRD4 inhibitors

Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention Against Triple-Negative Breast Cancer

Design, synthesis and biological evaluation of coumarin derivatives as potential BRD4 inhibitors

Design, Synthesis, and Biological Evaluation of 4,5-Dihydro-[1,2,4]triazolo[4,3-f]pteridine Derivatives As Novel Dual-Plk1/brd4 Inhibitors.

Design, synthesis and antitumor activity of novel 4-oxobutanamide derivatives